The Applications of the Novel Polymeric Fluoropyrimidine F10 in Cancer Treatment: Current Evidence

Overview

Journal Future Oncol

Specialty Oncology

Date 2016 Jun 10

PMID 27279153

Citations 22

Authors

William H Gmeiner

Waldemar Debinski

Carol Milligan

David Caudell

Timothy S Pardee

Affiliations

Soon will be listed here.

Abstract

F10 is a novel polymeric fluoropyrimidine drug candidate with strong anticancer activity in multiple preclinical models. F10 has strong potential for impacting cancer treatment because it displays high cytotoxicity toward proliferating malignant cells with minimal systemic toxicities thus providing an improved therapeutic window relative to traditional fluoropyrimidine drugs, such as 5-fluorouracil. F10 has a unique mechanism that involves dual targeting of thymidylate synthase and Top1. In this review, the authors provide an overview of the studies that revealed the novel aspects of F10's cytotoxic mechanism and summarize results obtained in preclinical models of acute myeloid leukemia, acute lymphocytic leukemia, glioblastoma and prostate cancer that demonstrate the strong potential of F10 to improve treatment outcomes.

Citing Articles

The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress.

Finan J, Di Niro R, Park S, Jeong K, Hedberg M, Smith A Cancer Biol Ther. 2024; 25(1):2421584.

PMID: 39513592 PMC: 11552260. DOI: 10.1080/15384047.2024.2421584.

Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs.

Fabrega C, Clua A, Eritja R, Avino A Curr Med Chem. 2021; 30(11):1304-1319.

PMID: 34844535 PMC: 11497139. DOI: 10.2174/0929867328666211129124039.

Evaluation of Floxuridine Oligonucleotide Conjugates Carrying Potential Enhancers of Cellular Uptake.

Avino A, Clua A, Bleda M, Eritja R, Fabrega C Int J Mol Sci. 2021; 22(11).

PMID: 34073599 PMC: 8199350. DOI: 10.3390/ijms22115678.

Parallel G-quadruplex Structures Increase Cellular Uptake and Cytotoxicity of 5-Fluoro-2'-deoxyuridine Oligomers in 5-Fluorouracil Resistant Cells.

Clua A, Fabrega C, Garcia-Chica J, Grijalvo S, Eritja R Molecules. 2021; 26(6).

PMID: 33804620 PMC: 8003610. DOI: 10.3390/molecules26061741.

AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with Inhibition.

Haber A, Jain A, Mani C, Nevler A, Agostini L, Golan T Mol Cancer Res. 2021; 19(4):565-572.

PMID: 33593942 PMC: 9013283. DOI: 10.1158/1541-7786.MCR-20-0985.

References

Liao Z, Sordet O, Zhang H, Kohlhagen G, Antony S, Gmeiner W . A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes. Cancer Res. 2005; 65(11):4844-51. DOI: 10.1158/0008-5472.CAN-04-1302. View

Grogan B, Parker J, Guminski A, Stivers J . Effect of the thymidylate synthase inhibitors on dUTP and TTP pool levels and the activities of DNA repair glycosylases on uracil and 5-fluorouracil in DNA. Biochemistry. 2011; 50(5):618-27. PMC: 3074591. DOI: 10.1021/bi102046h. View

Desai S, Zhang H, Rodriguez-Bauman A, Yang J, Wu X, Gounder M . Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol Cell Biol. 2003; 23(7):2341-50. PMC: 150741. DOI: 10.1128/MCB.23.7.2341-2350.2003. View

Bijnsdorp I, Comijn E, Padron J, Gmeiner W, Peters G . Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition. Oncol Rep. 2007; 18(1):287-91. DOI: 10.3892/or.18.1.287. View

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

Pardee T, Gomes E, Jennings-Gee J, Caudell D, Gmeiner W . Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Blood. 2012; 119(15):3561-70. PMC: 3325043. DOI: 10.1182/blood-2011-06-362442. View

Weiss M, Maslak P, Feldman E, Berman E, BERTINO J, Gee T . Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol. 1996; 14(9):2480-5. DOI: 10.1200/JCO.1996.14.9.2480. View

Gusella M, Frigo A, Bolzonella C, Marinelli R, Barile C, Bononi A . Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer. 2009; 100(10):1549-57. PMC: 2696766. DOI: 10.1038/sj.bjc.6605052. View

Shoemaker R . The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006; 6(10):813-23. DOI: 10.1038/nrc1951. View

10.

Pommier Y . Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006; 6(10):789-802. DOI: 10.1038/nrc1977. View

11.

Lin C, Ban Y, Lyu Y, Liu L . Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks. J Biol Chem. 2009; 284(41):28084-28092. PMC: 2788859. DOI: 10.1074/jbc.M109.030601. View

12.

Hanawalt P . A balanced perspective on unbalanced growth and thymineless death. Front Microbiol. 2015; 6:504. PMC: 4456962. DOI: 10.3389/fmicb.2015.00504. View

13.

Berlin J, Propert K, Trump D, Wilding G, Hudes G, Glick J . 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). Am J Clin Oncol. 1998; 21(2):171-6. DOI: 10.1097/00000421-199804000-00016. View

14.

Wielinga P, Westerhoff H, Lankelma J . The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells. Eur J Biochem. 2000; 267(3):649-57. DOI: 10.1046/j.1432-1327.2000.01030.x. View

15.

Khodursky A, Guzman E, Hanawalt P . Thymineless Death Lives On: New Insights into a Classic Phenomenon. Annu Rev Microbiol. 2015; 69:247-63. DOI: 10.1146/annurev-micro-092412-155749. View

16.

HOUGHTON J, Harwood F, Tillman D . Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc Natl Acad Sci U S A. 1997; 94(15):8144-9. PMC: 21571. DOI: 10.1073/pnas.94.15.8144. View

17.

Oudard S . Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev. 2012; 39(3):275-89. DOI: 10.1016/j.ctrv.2012.09.005. View

18.

Pardee T, Stadelman K, Jennings-Gee J, Caudell D, Gmeiner W . The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells. Oncotarget. 2014; 5(12):4170-9. PMC: 4147314. DOI: 10.18632/oncotarget.1937. View

19.

Veuger M, Honders M, Spoelder H, Willemze R, Barge R . Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines. Leuk Res. 2003; 27(5):445-53. DOI: 10.1016/s0145-2126(02)00224-2. View

20.

Dusenbury C, Davis M, Lawrence T, Maybaum J . Induction of megabase DNA fragments by 5-fluorodeoxyuridine in human colorectal tumor (HT29) cells. Mol Pharmacol. 1991; 39(3):285-9. View